Ye, M., Zhang, X., Li, N., Zhang, Y., Jing, P., Chang, N., . . . Zhang, J. (2016). ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget.

Ye, Mingxiang, Xinxin Zhang, Nan Li, Yong Zhang, Pengyu Jing, Ning Chang, Jianxiong Wu, Xinling Ren, και Jian Zhang. "ALK and ROS1 As Targeted Therapy Paradigms and Clinical Implications to Overcome Crizotinib Resistance." Oncotarget 2016.

Ye, Mingxiang, et al. "ALK and ROS1 As Targeted Therapy Paradigms and Clinical Implications to Overcome Crizotinib Resistance." Oncotarget 2016.